Jing Li Huang1, Scott Kizy1, Schelomo Marmor1, Ariella Altman1, Anne Blaes2, Heather Beckwith2, Todd M Tuttle1, Jane Yuet Ching Hui3. 1. Department of Surgery, University of Minnesota, Mayo Mail Code 195, 420 Delaware Street SE, Minneapolis, MN, 55455, USA. 2. Division of Hematology, Oncology, and Transplantation, University of Minnesota, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, MN, 55455, USA. 3. Department of Surgery, University of Minnesota, Mayo Mail Code 195, 420 Delaware Street SE, Minneapolis, MN, 55455, USA. jhui@umn.edu.
Abstract
PURPOSE: The 21-gene recurrence score (RS) assay is increasingly utilized to predict the risk of recurrence in early stage estrogen receptor (ER)-positive breast cancer. We hypothesize that tumor grade and progesterone receptor (PR) status predict RS categorization. METHODS: We identified women between the ages of 18 and 74 years with stage I or II, ER-positive, invasive carcinoma of the breast from the Surveillance Epidemiology End-Results database from 2010 to 2013. Multivariable logistic regression was performed to determine factors associated with high-risk RS. RESULTS: We identified 42,530 patients that met inclusion criteria. Multivariable logistic regression demonstrated that grade I tumors [OR (odds ratio) 0.33, 95% CI (confidence interval) 0.31-0.37] and PR positive (PR+) status (OR 0.16, 95% CI 0.15-0.17) were significantly less likely to be associated with high-risk RS. Of patients with grade I PR+ tumors, 1% was in the high-risk group by the traditional cutoffs and 4% was in the high-risk group by the TAILORx cutoffs. The percentage of patients with high-risk RS remained low for grade I PR+ tumors regardless of age, race, tumor size, and lymph node status. CONCLUSIONS: We found that grade I PR+ tumors are associated a < 5% probability of having high-risk RS regardless of other patient demographic or pathologic factors. This suggests that the histologic factors of grade and PR status should be taken into consideration before ordering the 21-gene recurrence score assay.
PURPOSE: The 21-gene recurrence score (RS) assay is increasingly utilized to predict the risk of recurrence in early stage estrogen receptor (ER)-positive breast cancer. We hypothesize that tumor grade and progesterone receptor (PR) status predict RS categorization. METHODS: We identified women between the ages of 18 and 74 years with stage I or II, ER-positive, invasive carcinoma of the breast from the Surveillance Epidemiology End-Results database from 2010 to 2013. Multivariable logistic regression was performed to determine factors associated with high-risk RS. RESULTS: We identified 42,530 patients that met inclusion criteria. Multivariable logistic regression demonstrated that grade I tumors [OR (odds ratio) 0.33, 95% CI (confidence interval) 0.31-0.37] and PR positive (PR+) status (OR 0.16, 95% CI 0.15-0.17) were significantly less likely to be associated with high-risk RS. Of patients with grade I PR+ tumors, 1% was in the high-risk group by the traditional cutoffs and 4% was in the high-risk group by the TAILORx cutoffs. The percentage of patients with high-risk RS remained low for grade I PR+ tumors regardless of age, race, tumor size, and lymph node status. CONCLUSIONS: We found that grade I PR+ tumors are associated a < 5% probability of having high-risk RS regardless of other patient demographic or pathologic factors. This suggests that the histologic factors of grade and PR status should be taken into consideration before ordering the 21-gene recurrence score assay.
Authors: Patrick Neven; Giuseppe Floris; Laurence Slembrouck; Isabelle Vanden Bempt; Hans Wildiers; Ann Smeets; Anne-Sophie Van Rompuy; Chantal Van Ongeval; Lynn Jongen; Caroline Weltens; Kevin Punie; Griet Hoste; Els Van Nieuwenhuysen; Sileny Han; Ines Nevelsteen Journal: Mod Pathol Date: 2021-02-08 Impact factor: 7.842
Authors: C van Dooijeweert; I O Baas; I A G Deckers; S Siesling; P J van Diest; E van der Wall Journal: Breast Cancer Res Treat Date: 2021-01-30 Impact factor: 4.872
Authors: Rowan T Chlebowski; Aaron K Aragaki; Garnet L Anderson; Kathy Pan; Marian L Neuhouser; JoAnn E Manson; Cynthia A Thomson; Yasmin Mossavar-Rahmani; Dorothy S Lane; Karen C Johnson; Jean Wactawski-Wende; Linda Snetselaar; Thomas E Rohan; Juhua Luo; Ana Barac; Ross L Prentice Journal: J Clin Oncol Date: 2020-02-07 Impact factor: 50.717